Amarin ($AMRN) will have to wait until the new year to find out whether its fish oil pill Vascepa will be approved for a wider indication. The FDA indefinitely delayed that decision, and it's reviewing the trial design of the New Jersey-based company's ANCHOR design in the meantime. The holdup apparently didn't put off investors, with shares spiking as much as 20% Friday morning. Story